TP53 and cancer: Across both TCGA and GENIE datasets, VHL and PBRM1 in KIRC, as well as TP53 in various cancer types, showed co-occurring mutations and CNDs that affected the highest proportions of samples within their respectively identified cancer types (Figure 1D–E, Supplementary Figure 1A, Tables S1E).